- Home
- NBY vs IKT Comparison
NBY vs IKT Comparison
Compare NBY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- IKT
- Stock Information
- Founded
- NBY 2000
- IKT 2008
- Country
- NBY United States
- IKT United States
- Employees
- NBY N/A
- IKT N/A
- Industry
- NBY
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- IKT Health Care
- Exchange
- NBY Nasdaq
- IKT Nasdaq
- Market Cap
- NBY 3.5M
- IKT 131.6M
- IPO Year
- NBY 2007
- IKT 2020
- Fundamental
- Price
- NBY $0.62
- IKT $1.93
- Analyst Decision
- NBY Strong Buy
- IKT Buy
- Analyst Count
- NBY 1
- IKT 2
- Target Price
- NBY $0.85
- IKT $8.00
- AVG Volume (30 Days)
- NBY 32.4K
- IKT 514.7K
- Earning Date
- NBY 08-12-2025
- IKT 08-13-2025
- Dividend Yield
- NBY N/A
- IKT N/A
- EPS Growth
- NBY N/A
- IKT N/A
- EPS
- NBY 0.57
- IKT N/A
- Revenue
- NBY $9,781,000.00
- IKT N/A
- Revenue This Year
- NBY $23.91
- IKT N/A
- Revenue Next Year
- NBY $32.05
- IKT N/A
- P/E Ratio
- NBY $1.34
- IKT N/A
- Revenue Growth
- NBY 20.52
- IKT N/A
- 52 Week Low
- NBY $0.36
- IKT $1.12
- 52 Week High
- NBY $2.45
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- NBY 56.70
- IKT 50.55
- Support Level
- NBY $0.58
- IKT $1.56
- Resistance Level
- NBY $0.64
- IKT $2.04
- Average True Range (ATR)
- NBY 0.03
- IKT 0.14
- MACD
- NBY 0.00
- IKT 0.01
- Stochastic Oscillator
- NBY 62.38
- IKT 61.22
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.